Can-Fite BioPharma (CANF) & Its Peers Critical Contrast

Can-Fite BioPharma (NYSE:CANF) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Can-Fite BioPharma to related businesses based on the strength of its valuation, risk, earnings, institutional ownership, analyst recommendations, dividends and profitability.

Valuation and Earnings

This table compares Can-Fite BioPharma and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Can-Fite BioPharma	$405,000.00	-$7.63 million	-0.11
Can-Fite BioPharma Competitors	$3.54 billion	$3.17 billion	550.65

Can-Fite BioPharma’s competitors have higher revenue and earnings than Can-Fite BioPharma. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Can-Fite BioPharma has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, Can-Fite BioPharma’s competitors have a beta of -3.70, meaning that their average share price is 470% less volatile than the S&P 500.

Insider & Institutional Ownership

21.0% of Can-Fite BioPharma shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 0.8% of Can-Fite BioPharma shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Can-Fite BioPharma and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Can-Fite BioPharma	N/A	N/A	N/A
Can-Fite BioPharma Competitors	-2,372.59%	-220.82%	-15.99%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Can-Fite BioPharma and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Can-Fite BioPharma	0	1	2	0	2.67
Can-Fite BioPharma Competitors	7792	13885	25777	1037	2.41

Can-Fite BioPharma presently has a consensus price target of $44.00, suggesting a potential upside of 2,616.05%. As a group, “Pharmaceuticals” companies have a potential upside of 25.48%. Given Can-Fite BioPharma’s stronger consensus rating and higher possible upside, analysts plainly believe Can-Fite BioPharma is more favorable than its competitors.

Summary

Can-Fite BioPharma beats its competitors on 7 of the 13 factors compared.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.